Response to trametinib of a pulmonary Langerhans cell histiocytosis harboring a MAP2K1 deletion

Gwenaël Lorillon; Fanelie Jouenne; Barouyr Baroudjian; Constance de Margerie-Mellon; Laetitia Vercellino; Véronique Meignin; Celeste Lebbe; Robert Vassallo; Samia Mourah; Abdellatif Tazi

doi:10.1164/rccm.201802-0275LE

Response to trametinib of a pulmonary Langerhans cell histiocytosis harboring a MAP2K1 deletion

Gwenaël Lorillon, Fanelie Jouenne, Barouyr Baroudjian, Constance de Margerie-Mellon, Laetitia Vercellino, Véronique Meignin, Celeste Lebbe, Robert Vassallo, Samia Mourah, Abdellatif Tazi

Pulmonary and Critical Care Medicine

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	675-678
Number of pages	4
Journal	American journal of respiratory and critical care medicine
Volume	198
Issue number	5
DOIs	https://doi.org/10.1164/rccm.201802-0275LE
State	Published - Sep 1 2018

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine

Access to Document

10.1164/rccm.201802-0275LE

Cite this

Lorillon, G, Jouenne, F, Baroudjian, B, de Margerie-Mellon, C, Vercellino, L, Meignin, V, Lebbe, C, Vassallo, R, Mourah, S & Tazi, A 2018, 'Response to trametinib of a pulmonary Langerhans cell histiocytosis harboring a MAP2K1 deletion', American journal of respiratory and critical care medicine, vol. 198, no. 5, pp. 675-678. https://doi.org/10.1164/rccm.201802-0275LE

@article{a39a7d1acc614f85a20e25f46ba7b049,

title = "Response to trametinib of a pulmonary Langerhans cell histiocytosis harboring a MAP2K1 deletion",

author = "Gwena{\"e}l Lorillon and Fanelie Jouenne and Barouyr Baroudjian and {de Margerie-Mellon}, Constance and Laetitia Vercellino and V{\'e}ronique Meignin and Celeste Lebbe and Robert Vassallo and Samia Mourah and Abdellatif Tazi",

note = "Funding Information: Supported by Award No. R01 HL089897 and Award No. R01 HL089856 from the NHLBI. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NHLBI or the NIH. The COPDGene project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board composed of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. M.E. was supported by unrestricted grants from the Swedish Society of Medicine, the Swedish Respiratory Society, the Swedish Heart–Lung Foundation, the Scientific Committee of Blekinge County Council, the Wera and Emil Cornell Foundation, and the Swedish Society for Medical Research. No funding organization had a role in the design and conduct of the study, in the analysis and interpretation of data, or in the preparation or approval of the manuscript to be submitted. Author Contributions: Conception and design: M.E.; analysis and interpretation: M.E., A.B.-H., N.W., D.C.C., and N.M.; drafting the manuscript for important intellectual content: M.E. and A.B.-H.; revising the manuscript for important intellectual content and approval of the final version to be published: M.E., A.B.-H., N.W., D.C.C., and N.M. Funding Information: Supported by a grant from the Legs Poix Chancellerie des Universit{\'e}s de Paris.",

year = "2018",

month = sep,

day = "1",

doi = "10.1164/rccm.201802-0275LE",

language = "English (US)",

volume = "198",

pages = "675--678",

journal = "American Review of Respiratory Disease",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "5",

}

TY - JOUR

T1 - Response to trametinib of a pulmonary Langerhans cell histiocytosis harboring a MAP2K1 deletion

AU - Lorillon, Gwenaël

AU - Jouenne, Fanelie

AU - Baroudjian, Barouyr

AU - de Margerie-Mellon, Constance

AU - Vercellino, Laetitia

AU - Meignin, Véronique

AU - Lebbe, Celeste

AU - Vassallo, Robert

AU - Mourah, Samia

AU - Tazi, Abdellatif

N1 - Funding Information: Supported by Award No. R01 HL089897 and Award No. R01 HL089856 from the NHLBI. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NHLBI or the NIH. The COPDGene project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board composed of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. M.E. was supported by unrestricted grants from the Swedish Society of Medicine, the Swedish Respiratory Society, the Swedish Heart–Lung Foundation, the Scientific Committee of Blekinge County Council, the Wera and Emil Cornell Foundation, and the Swedish Society for Medical Research. No funding organization had a role in the design and conduct of the study, in the analysis and interpretation of data, or in the preparation or approval of the manuscript to be submitted. Author Contributions: Conception and design: M.E.; analysis and interpretation: M.E., A.B.-H., N.W., D.C.C., and N.M.; drafting the manuscript for important intellectual content: M.E. and A.B.-H.; revising the manuscript for important intellectual content and approval of the final version to be published: M.E., A.B.-H., N.W., D.C.C., and N.M. Funding Information: Supported by a grant from the Legs Poix Chancellerie des Universités de Paris.

PY - 2018/9/1

Y1 - 2018/9/1

UR - http://www.scopus.com/inward/record.url?scp=85052692697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052692697&partnerID=8YFLogxK

U2 - 10.1164/rccm.201802-0275LE

DO - 10.1164/rccm.201802-0275LE

M3 - Letter

C2 - 29694792

AN - SCOPUS:85052692697

SN - 1073-449X

VL - 198

SP - 675

EP - 678

JO - American Review of Respiratory Disease

JF - American Review of Respiratory Disease

IS - 5

ER -

Response to trametinib of a pulmonary Langerhans cell histiocytosis harboring a MAP2K1 deletion

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this